Company Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Why Investors Should Care
Offers a dividend yield of 2.55%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $44.33B (+5.7% YoY); net profit $6.52B.
- Trailing 12 Months Year-on-year growth — revenue +13.0%, earnings -47.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.5%, profit CAGR -2.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.51% |
| 1 Year: | 13.00% |
Compounded Profit Growth
| 5 Years: | -2.01% |
| 1 Year: | -47.50% |
Stock Price Performance
| 1 Year: | -18.95% |
| 6 Months: | +12.32% |
| 3 Months: | +0.08% |
| 1 Month: | -0.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)51.73 · Neutral
P/E of 33.07 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.55%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -2.0% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABT Abbott Laboratories SPXR3KPHARMA | 102.51 | 33.07 | $178.55B | 2.55% | 12.76% | 10.58% | 0.51% | -2.01% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 6.33B | 6.64B | 6.83B | 7.59B | 7.39B | 7.77B | 7.66B | 7.76B | 7.54B | 7.98B | 8.08B | 8.31B | 7.73B | 7.33B | 8.85B | 10.46B | 10.22B | 10.93B | 11.89B | 11.26B | 10.41B | 9.75B | 9.98B | 10.14B | 9.96B | 10.38B | 10.63B | 10.36B | 11.14B | 11.37B | 11.46B | 11.16B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.47B | 4.85B | 5.08B | 4.92B | 4.89B | - |
| Gross Profit | 2.80B | 2.76B | 2.84B | 2.60B | 2.90B | 2.88B | 2.90B | 2.75B | 3.06B | 3.45B | 3.75B | 3.74B | 3.92B | 3.95B | 4.09B | 3.89B | 4.22B | 4.23B | 4.40B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.89B | 6.29B | 6.29B | 6.54B | 6.27B | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.20B | 4.24B | 4.24B | 4.29B | 4.93B | - |
| Operating Income | 729.00M | 713.00M | - | 524.00M | 816.00M | 897.00M | - | -242.00M | 386.00M | 769.00M | - | 608.00M | 882.00M | 995.00M | - | 739.00M | 1.21B | 1.20B | - | 758.00M | 672.00M | 1.50B | 2.11B | 1.39B | 2.55B | 2.91B | 2.38B | 1.77B | 1.51B | 1.54B | 1.65B | 1.39B | 1.67B | 1.86B | 1.69B | 2.05B | 2.06B | 2.25B | 1.34B | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.67B | 3.05B | 3.09B | 3.27B | 2.43B | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 131.00M | 121.00M | 121.00M | 120.00M | 174.00M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.78B | 2.15B | 2.18B | 2.36B | 1.45B | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 453.00M | 371.00M | 536.00M | 582.00M | 372.00M | - |
| Net Income | 784.00M | 580.00M | 767.00M | 316.00M | 615.00M | -329.00M | 798.00M | 419.00M | 283.00M | 603.00M | -828.00M | 418.00M | 733.00M | 563.00M | 654.00M | 672.00M | 1.01B | 960.00M | 1.05B | 564.00M | 537.00M | 1.23B | 1.79B | 1.19B | 2.10B | 2.45B | 2.02B | 1.44B | 1.32B | 1.38B | 1.44B | 1.23B | 1.30B | 1.65B | 1.32B | 1.78B | 1.64B | 1.78B | 1.08B | - |
| Diluted EPS | 0.52 | 0.38 | 0.51 | 0.21 | 0.41 | -0.22 | 0.53 | 0.24 | 0.16 | 0.34 | -0.48 | 0.23 | 0.41 | 0.32 | 0.37 | 0.38 | 0.56 | 0.53 | 0.59 | 0.31 | 0.30 | 0.69 | 1.00 | 0.66 | 1.17 | 1.37 | 1.14 | 0.81 | 0.75 | 0.78 | 0.82 | 0.70 | 0.74 | 0.94 | - | 1.01 | 0.94 | 1.01 | 0.61 | 0.53 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 589.00M | 575.00M | 574.00M | - | 672.00M | 577.00M | 596.00M | - | 578.00M | 564.00M | 580.00M | 654.00M | 654.00M | 672.00M | 697.00M | 684.00M | 782.00M | 654.00M | 715.00M | 672.00M | 684.00M | 698.00M | 713.00M | 716.00M | 725.00M | 766.00M | - | 767.00M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.91B | 29.53B | 30.76B | 35.17B | 21.41B | 19.05B | 19.66B | 20.25B | 20.41B | 20.85B | 27.39B | 30.58B | 31.90B | 34.61B | - | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.14B | 17.98B | 18.71B | 19.32B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.51B | 22.13B | 23.24B | 25.01B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.15B | 15.66B | 16.42B | 16.96B |
| Operating Income | 4.58B | 5.69B | 6.24B | 6.09B | 1.63B | 1.36B | 2.13B | 2.60B | 2.87B | 3.03B | 1.56B | 3.65B | 4.53B | 5.36B | - | 8.36B | 6.48B | 6.83B | 8.05B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.13B | 10.54B | 10.79B | 12.07B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 558.00M | 637.00M | 559.00M | 493.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.31B | 6.66B | 7.01B | 8.47B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37B | 941.00M | -6.39B | 1.94B |
| Net Income | - | - | 5.75B | 4.63B | 4.73B | 5.96B | 2.58B | 2.28B | 4.42B | 1.40B | 477.00M | 2.37B | 3.69B | 4.50B | - | 6.93B | 5.72B | 13.40B | 6.52B |
| Diluted EPS | 2.31 | 3.12 | 3.69 | 2.96 | 3.01 | 3.72 | 1.62 | 1.49 | 2.92 | 0.94 | 0.27 | 1.33 | 2.06 | 2.50 | - | 3.91 | 3.26 | 7.64 | 3.72 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 2.26B | 2.30B | 2.44B | 2.42B | 2.74B | 2.89B | 2.74B | 2.84B | 2.94B |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 39.71B | 42.42B | 52.58B | 60.57B | 60.28B | 67.23B | 42.94B | 41.21B | 41.25B | 52.67B | 76.25B | 67.17B | 67.89B | 72.55B | - | 74.44B | 73.21B | 81.41B | 86.71B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.22B | 22.67B | 23.66B | 26.00B |
| Cash & Equivalents | 521.19M | 2.46B | 4.11B | 8.81B | 3.65B | 6.81B | 10.80B | 3.48B | 4.06B | 5.00B | 18.62B | 9.41B | 3.84B | 3.86B | 6.84B | - | 9.88B | 6.90B | 7.62B | 8.52B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.17B | 6.57B | 6.19B | 6.49B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.22B | 6.57B | 6.92B | 7.93B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.53B | 34.39B | 33.51B | 33.94B |
| Current Liabilities | - | 9.10B | 11.59B | 13.05B | 17.26B | 15.48B | 13.28B | 9.51B | 10.47B | 9.19B | 6.66B | 8.91B | 9.01B | 10.86B | 11.91B | - | 15.49B | 13.84B | 14.16B | 16.50B |
| Long Term Debt | - | 9.49B | 8.71B | 11.27B | 12.52B | 12.04B | 18.09B | 3.39B | 3.39B | 5.87B | 20.68B | 27.21B | 19.36B | 16.66B | 18.53B | - | 14.52B | 13.60B | 12.62B | 9.90B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.72B | 15.63B | 15.02B | 13.86B |
| Total Equity | 14.05B | 17.78B | 17.48B | 23.14B | 22.68B | 24.44B | 26.72B | 25.17B | 21.53B | 21.21B | 20.54B | 30.90B | 30.52B | 31.09B | 32.78B | - | 36.69B | 38.60B | 47.66B | 52.13B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.99B | 1.99B | 1.99B | 2.00B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | 8.97B | 9.31B | 3.32B | 3.67B | 2.97B | 3.20B | 5.57B | 6.30B | 6.14B | 7.90B | - | 9.58B | 7.26B | 8.56B | 9.57B |
| Investing Cash Flow | - | -2.09B | -3.70B | -12.19B | 661.00M | -5.56B | -3.93B | -202.00M | 406.00M | -248.00M | -9.62B | -1.36B | -1.81B | -2.21B | - | -1.74B | -3.13B | -2.34B | -2.42B |
| Financing Cash Flow | - | -3.49B | 1.00B | -1.09B | -6.42B | 195.00M | -6.70B | -2.74B | -2.24B | 11.15B | -5.28B | -10.39B | -4.29B | -2.78B | - | -7.64B | -7.09B | -5.40B | -6.31B |
| Capital Expenditure | -1.66B | -1.29B | -1.09B | -1.02B | -1.49B | -1.79B | -1.15B | -1.08B | -1.11B | -1.12B | -1.14B | -1.39B | -1.64B | -2.18B | - | -1.78B | -2.20B | -2.21B | -2.17B |
| Free Cash Flow | - | - | - | - | 7.48B | 7.52B | 2.18B | 2.60B | 1.86B | 2.08B | 4.43B | 4.91B | 4.50B | 5.72B | - | 7.80B | 5.06B | 6.35B | 7.39B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 205.00M | -2.96B | 816.00M | 835.00M |
| Share Buybacks | 1.06B | 1.08B | 826.35M | 866.83M | 77.00M | 2.36B | 1.60B | 2.19B | 2.24B | 522.00M | 117.00M | 238.00M | 718.00M | 403.00M | 2.30B | 3.79B | 1.23B | 1.29B | 893.00M |
| Dividends Paid | 1.96B | 2.17B | 2.41B | 2.67B | 2.94B | 3.18B | 882.00M | 1.34B | 1.44B | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.1% | 55.2% | 55.4% | 56.4% |
| Operating Margin % | 17.7% | 19.3% | 20.3% | 17.3% | 7.6% | 7.1% | 10.9% | 12.8% | 14.1% | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | - | 19.2% | 16.2% | 16.3% | 18.2% |
| Net Margin % | - | - | 18.7% | 13.2% | 22.1% | 31.3% | 13.1% | 11.3% | 21.7% | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | - | 15.9% | 14.3% | 31.9% | 14.7% |
| ROE % | - | - | 24.8% | 20.4% | 19.3% | 22.3% | 10.2% | 10.6% | 20.9% | 6.8% | 1.5% | 7.8% | 11.9% | 13.7% | - | 18.9% | 14.8% | 28.1% | 12.5% |
| ROCE % | 15.0% | 18.5% | 15.8% | 14.1% | 3.6% | 2.5% | 6.4% | 8.5% | 8.9% | 6.6% | 2.3% | 6.3% | 7.9% | 8.8% | - | 14.2% | 10.9% | 10.1% | 11.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.82% | 152.56M | $15.20B |
| 2 | Vanguard Capital Management LLC | 6.57% | 113.75M | $11.33B |
| 3 | State Street Corporation | 4.68% | 80.93M | $8.06B |
| 4 | Charles Schwab Investment Management, Inc. | 3.45% | 59.67M | $5.94B |
| 5 | Vanguard Portfolio Management LLC | 2.83% | 49.02M | $4.88B |
| 6 | Geode Capital Management, LLC | 2.27% | 39.22M | $3.91B |
| 7 | Capital Research Global Investors | 2.13% | 36.91M | $3.68B |
| 8 | Capital International Investors | 2.00% | 34.65M | $3.45B |
| 9 | Morgan Stanley | 1.54% | 26.61M | $2.65B |
| 10 | NORGES BANK | 1.35% | 23.35M | $2.33B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABT
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device
FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention devi…
Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says
Abbott Laboratories' (ABT) 2026 guidance cuts were driven by headwinds related to its diabetes and e
Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs
Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Australia Bionic Devices Market Report by Product, Fixation, Technology, End User, States and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering. According to the rep…
India regulator pulls up Nestlé, Abbott over infant-formula violations
The FSSAI issued a notice to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for whey protein claims.
Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.
Abbott to spin-off nutrition into standalone business
The US group said the decision addresses “different investment identities and requirements, growth profiles, and innovation cycles”.
ABT — Frequently Asked Questions
What is the current share price of Abbott Laboratories (ABT)?
As of 2026-10-22 16:30 PDT, Abbott Laboratories (ABT) trades at $102.51 on NYSE. Its 52-week range is $81.47 to $133.53.
What is the market capitalisation of ABT?
Abbott Laboratories (ABT) has a market capitalisation of $178.55B on NYSE.
What is the P/E ratio of ABT?
ABT trades at a trailing price-to-earnings (P/E) ratio of 33.07. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 3.37.
Does ABT pay a dividend?
Abbott Laboratories (ABT) currently offers a dividend yield of 2.55%.
What is the return on equity (ROE) of ABT?
ABT has a return on equity (ROE) of 10.58%. Its return on capital employed (ROCE) is 12.76%.
Is ABT a good stock to buy?
This page provides a data-driven analysis of Abbott Laboratories (ABT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.